Molecules with specificity for CD79 and CD22
AssigneeUcb Biopharma Sprl
InventorsHelene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
Claims11
A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b,
- wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO:
- 128 for CDRH1, SEQ ID NO:
- 129 for CDRH2 and SEQ ID NO:
- 130 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 125 for CDRL1, SEQ ID NO:
- 126 for CDRL2 and SEQ ID NO:
- 127 for CDRL3;
- or
- comprises 3 heavy chain CDRs comprising SEQ ID NO:
- 138 for CDRH1, SEQ ID NO:
- 139 wherein the Cys has been replaced by Ser for CDRH2 and SEQ ID NO:
- 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 135 for CDRL1, SEQ ID NO:
- 136 for CDRL2 and SEQ ID NO:
- 137 for CDRL3;
- and
- wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising specific for CD79b and comprises 3 heavy chain CDRs comprising SEQ ID NO:
- 78 for CDRH1, SEQ ID NO:
- 79 for CDRH2 and SEQ ID NO:
- 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 75 for CDRL1, SEQ ID NO:
- 76 for CDRL2 and SEQ ID NO:
- 77 for CDRL3;
- or
- 3 heavy chain CDRs comprising SEQ ID NO:
- 78 for CDRH1, SEQ ID NO:
- 79 for CDRH2 and SEQ ID NO:
- 80 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 85 for CDRL1, SEQ ID NO:
- 86 for CDRL2 and SEQ ID NO:
- 87 for CDRL3;
- or
- 3 heavy chain CDRs comprising SEQ ID NO:
- 88 for CDRH1, SEQ ID NO:
- 89 for CDRH2 and SEQ ID NO:
- 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 85 for CDRL1, SEQ ID NO:
- 86 for CDRL2 and SEQ ID NO:
- 87 for CDRL3;
- or
- 3 heavy chain CDRs comprising SEQ ID NO:
- 88 for CDRH1, SEQ ID NO:
- 89 for CDRH2 and SEQ ID NO:
- 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 75 for CDRL1, SEQ ID NO:
- 76 for CDRL2 and SEQ ID NO:
- 77 for CDRL3.
A multispecific molecule comprising a binding domain specific to human antigen CD22 and a binding domain specific to human antigen CD79b, wherein the binding domain specific to human antigen CD22 comprises 3 heavy chain CDRs comprising SEQ ID NO:
- 138 for CDRH1, SEQ ID NO:
- 139, wherein Cys has been replaced by Ser for CDRH2 and SEQ ID NO:
- 140 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 135 for CDRL1, SEQ ID NO:
- 136 for CDRL2and SEQ ID NO:
- 137 for CDRL3;
- and
- wherein the binding domain specific to human CD79b comprises 3 heavy chain CDRs comprising SEQ ID NO:
- 88 for CDRH1, SEQ ID NO:
- 89 for CDRH2 and SEQ ID NO:
- 90 for CDRH3 and 3 light chain CDRs comprising SEQ ID NO:
- 85 for CDRL1, SEQ ID NO:
- 86 for CDRL2 and SEQ ID NO:
- 87 for CDRL3.
Dependencies are inferred from the claim text.